vs
Side-by-side financial comparison of Aspire Biopharma Holdings, Inc. (ASBP) and NOAH HOLDINGS LTD (NOAH). Click either name above to swap in a different company.
NOAH HOLDINGS LTD is the larger business by last-quarter revenue ($2.3K vs $1.9K, roughly 1.2× Aspire Biopharma Holdings, Inc.).
Aspire Biopharma Holdings, Inc. is a clinical-stage biopharmaceutical firm focused on developing novel therapeutic candidates for unmet needs in oncology and rare diseases, with primary operations across North America and key Asia-Pacific markets.
Noah Holdings is a Chinese financial services company headquartered in Shanghai, China. It is the largest independent wealth management company in China.
ASBP vs NOAH — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.9K | $2.3K |
| Net Profit | $-1.9M | — |
| Gross Margin | 45.5% | — |
| Operating Margin | -59015.8% | 69.3% |
| Net Margin | -95337.1% | — |
| Revenue YoY | — | — |
| Net Profit YoY | -755.6% | — |
| EPS (diluted) | $-0.04 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $2.3K | ||
| Q3 25 | $1.9K | $24.6M | ||
| Q2 25 | — | $2.4K | ||
| Q1 25 | — | $48.8M | ||
| Q4 24 | — | $9.2K | ||
| Q3 24 | — | $24.2K |
| Q4 25 | — | — | ||
| Q3 25 | $-1.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 45.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | 69.3% | ||
| Q3 25 | -59015.8% | — | ||
| Q2 25 | — | 73.8% | ||
| Q1 25 | — | 24.2% | ||
| Q4 24 | — | 29.8% | ||
| Q3 24 | — | 20.0% |
| Q4 25 | — | — | ||
| Q3 25 | -95337.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | $-0.04 | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $96.8K |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-11.5M | — |
| Total Assets | $2.4M | $223.8K |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $96.8K | ||
| Q3 25 | — | $14.6M | ||
| Q2 25 | — | $102.5K | ||
| Q1 25 | — | $698.3M | ||
| Q4 24 | — | $93.1K | ||
| Q3 24 | — | $111.9K |
| Q4 25 | — | — | ||
| Q3 25 | $-11.5M | $26.0M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $1.4B | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $184.8K |
| Q4 25 | — | $223.8K | ||
| Q3 25 | $2.4M | $31.6M | ||
| Q2 25 | — | $225.8K | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $226.6K | ||
| Q3 24 | — | $236.7K |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.1M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | $-1.1M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $53.1M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $41.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 85.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
